↓ Skip to main content

Redefining extended-spectrum β-lactamases: balancing science and clinical need

Overview of attention for article published in Journal of Antimicrobial Chemotherapy (JAC), October 2008
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Citations

dimensions_citation
92 Dimensions

Readers on

mendeley
239 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Redefining extended-spectrum β-lactamases: balancing science and clinical need
Published in
Journal of Antimicrobial Chemotherapy (JAC), October 2008
DOI 10.1093/jac/dkn444
Pubmed ID
Authors

Christian G. Giske, Arnfinn S. Sundsfjord, Gunnar Kahlmeter, Neil Woodford, Patrice Nordmann, David L. Paterson, Rafael Cantón, Timothy R. Walsh

Abstract

The current beta-lactamase classifications have reached a high level of complexity, making them less accessible to clinicians, infection control professionals, hospital management and politicians. From the clinical perspective, a revised comprehensible nomenclature scheme is therefore needed. The term extended-spectrum beta-lactamases (ESBLs) has reached a broader audience over time, but is currently restricted to functional class 2be/molecular class A, clavulanic acid inhibited enzymes with activity against extended-spectrum cephalosporins. The proposed new classification expands the definition of ESBL to other clinically important acquired beta-lactamases with activity against extended-spectrum cephalosporins and/or carbapenems. The classical class A ESBLs have been designated ESBLA in this classification, whereas plasmid-mediated AmpC and OXA-ESBLs are classed as miscellaneous ESBLs (ESBLM). Lastly, the carbapenemases have been designated ESBLCARBA, ESBLs with hydrolytic activity against carbapenems. We believe that this simplified classification may encourage new groups of healthcare professionals to engage in the effort to prevent the spread of acquired beta-lactamases.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 239 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 4 2%
Spain 2 <1%
India 1 <1%
United Kingdom 1 <1%
Unknown 231 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 37 15%
Student > Ph. D. Student 35 15%
Researcher 31 13%
Student > Postgraduate 21 9%
Student > Bachelor 20 8%
Other 55 23%
Unknown 40 17%
Readers by discipline Count As %
Medicine and Dentistry 74 31%
Agricultural and Biological Sciences 44 18%
Biochemistry, Genetics and Molecular Biology 27 11%
Immunology and Microbiology 25 10%
Veterinary Science and Veterinary Medicine 5 2%
Other 15 6%
Unknown 49 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 July 2022.
All research outputs
#3,274,602
of 25,373,627 outputs
Outputs from Journal of Antimicrobial Chemotherapy (JAC)
#1,264
of 8,174 outputs
Outputs of similar age
#10,646
of 103,375 outputs
Outputs of similar age from Journal of Antimicrobial Chemotherapy (JAC)
#6
of 48 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,174 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 103,375 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.